Published in World J Surg on April 01, 2006
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res (2008) 2.00
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med (2013) 1.76
A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun (2009) 1.36
Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem (2012) 1.34
Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. Cancer Res (2008) 1.34
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics (2015) 0.94
Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjug Chem (2012) 0.93
T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol Res (2014) 0.85
(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy. J Nucl Med (2016) 0.83
Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice. Prostate (2015) 0.79
Identifying cancer origin using circulating tumor cells. Cancer Biol Ther (2016) 0.78
[Immunohistochemical algorithms in prostate diagnostics: what's new?]. Pathologe (2009) 0.77
A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen. Mol Pharm (2013) 0.77
Laser ablation-based one-step generation and bio-functionalization of gold nanoparticles conjugated with aptamers. J Nanobiotechnology (2010) 0.77
DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening. Nucleic Acids Res (2016) 0.75
Anti-tumor effects of a recombinant anti-prostate specific membrane antigen immunotoxin against prostate cancer cells. BMC Urol (2017) 0.75
Study of NGEP expression in androgen sensitive prostate cancer cells: A potential target for immunotherapy. Med J Islam Repub Iran (2015) 0.75
PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics. Sci Rep (2017) 0.75
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to loco-regional therapies. Cancer Sci (2017) 0.75
Well-Differentiated Thyroid Cancer Neovasculature Expresses Prostate-Specific Membrane Antigen-a Possible Novel Therapeutic Target. Endocr Pathol (2017) 0.75
The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells. J Cancer (2017) 0.75
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem (2004) 3.49
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol (2005) 3.01
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res (1993) 2.22
Expression of the prostate-specific membrane antigen. Cancer Res (1994) 2.06
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology (1998) 2.04
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res (1988) 1.91
Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A (1996) 1.70
Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB). Enzyme Nomenclature. Recommendations 1992. Supplement 4: corrections and additions (1997). Eur J Biochem (1997) 1.67
Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res (1997) 1.44
Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res (1995) 1.43
Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer (1995) 1.43
Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome (2001) 1.36
A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res (2004) 1.24
A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate (2000) 1.21
Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A (2003) 1.18
Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol (2000) 1.13
Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity. J Biol Chem (1999) 1.11
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer (2003) 1.10
Molecular cloning of a peptidase against N-acetylaspartylglutamate from a rat hippocampal cDNA library. J Neurochem (1997) 1.04
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate (2002) 1.03
Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res (1998) 1.03
Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate (2004) 1.02
Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther (1998) 1.01
Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res (2000) 0.99
Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology (1998) 0.96
Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urol (1998) 0.95
Molecular expression of PSMA mRNA and protein in primary renal tumors. Int J Cancer (1999) 0.92
Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. Proc Natl Acad Sci U S A (1998) 0.88
Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356. J Urol (1994) 0.85
Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer. Prostate Cancer Prostatic Dis (2005) 0.85
Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? Clin Cancer Res (2000) 0.84
Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. Int J Cancer (2002) 0.79
Role of glutamate receptors in the development and maintenance of bladder overactivity after cerebral infarction in the rat. J Urol (2004) 0.78
Characteristics of a purified dog hepatic microsomal N,O-acyltransferase. Carcinogenesis (1994) 0.77
Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res (2007) 3.51
Positive end-expiratory pressure after a recruitment maneuver prevents both alveolar collapse and recruitment/derecruitment. Am J Respir Crit Care Med (2003) 2.06
The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol (2008) 1.93
Instillation of mitomycin C after transurethral resection of bladder cancer impairs wound healing: an animal model. Anticancer Res (2011) 1.50
Higher than expected association of clinical prostate and bladder cancers. J Urol (2008) 1.49
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Finding unrecognized information in overactive bladder clinical trial data: a new approach to understanding placebo and treatment effects. Neurourol Urodyn (2012) 1.40
Efficacy of naftopidil for nocturia in male patients with lower urinary tract symptoms: comparison of morning and evening dosing. Int J Urol (2014) 1.39
N-Acetyltransferases and the susceptibility to benzidine-induced bladder carcinogenesis. Int J Cancer (2007) 1.38
Antimuscarinic use among individuals with urinary incontinence who reside in long-term care facilities. Int Urol Nephrol (2013) 1.38
Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol (2008) 1.28
The spectrum of eosinophilic cystitis in males: case series and literature review. Arch Pathol Lab Med (2009) 1.24
The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma. Cancer Res (2006) 1.17
Atrial myxomas: pathologic types, tumor location, and presenting symptoms. J Card Surg (2006) 1.16
Diet and prostate cancer. Toxicology (2002) 1.07
Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J Surg Res (2003) 1.06
Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. Trends Mol Med (2011) 1.06
Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. BJU Int (2008) 1.04
Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem Pharmacol (2005) 1.04
Characterization of prostate cancer missed by sextant biopsy. Clin Prostate Cancer (2003) 1.03
Shape Signatures: speeding up computer aided drug discovery. Drug Discov Today (2006) 1.03
The role of prevalence in the diagnosis of prostate cancer. Cancer Control (2006) 1.02
Prevention by natural food anthocyanins, purple sweet potato color and red cabbage color, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-associated colorectal carcinogenesis in rats initiated with 1,2-dimethylhydrazine. J Toxicol Sci (2002) 1.01
Epidemiology of prostate cancer in Africa: another step in the understanding of the disease? Curr Probl Cancer (2007) 1.01
Lung toxicity of 16 fine particles on intratracheal instillation in a bioassay model using f344 male rats. Toxicol Pathol (2008) 0.99
Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Cancer Res (2003) 0.99
Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors. Int J Oncol (2004) 0.99
Higher than expected association of clinical prostate and bladder cancers. J Urol (2005) 0.97
Saturation biopsies for prostate cancer: current uses and future prospects. Nat Rev Urol (2009) 0.95
Value of GST-P positive preneoplastic hepatic foci in dose-response studies of hepatocarcinogenesis: evidence for practical thresholds with both genotoxic and nongenotoxic carcinogens. A review of recent work. Toxicol Pathol (2003) 0.94
Cyclin B1, unlike cyclin G1, increases significantly during colorectal carcinogenesis and during later metastasis to lymph nodes. Int J Oncol (2003) 0.93
Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway. J Toxicol Sci (2012) 0.92
Telmisartan inhibits human urological cancer cell growth through early apoptosis. Exp Ther Med (2010) 0.92
The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells. Int J Mol Med (2003) 0.92
Cyclin A correlates with carcinogenesis and metastasis, and p27(kip1) correlates with lymphatic invasion, in colorectal neoplasms. Hum Pathol (2002) 0.92
Correlation of the genotypes for N-acetyltransferases 1 and 2 with double bladder and prostate cancers in a case-comparison study. Anticancer Res (2003) 0.91
An intratracheal instillation bioassay system for detection of lung toxicity due to fine particles in f344 rats. J Toxicol Pathol (2009) 0.91
Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer (2004) 0.90
Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas. Carcinogenesis (2005) 0.90
Molecular analysis of carcinogen-induced rodent lung tumors: Involvement of microRNA expression and Krαs or Egfr mutations. Mol Med Rep (2011) 0.89
Immunohistochemically detected expression of p27(Kip1) and Skp2 predicts survival in patients with intrahepatic cholangiocarcinomas. Ann Surg Oncol (2008) 0.89
The effects of cyclooxygenase-2 inhibitors on urological cancer cells. Int J Mol Med (2004) 0.88
Lack of mutation induction with exposure to 1.5 GHz electromagnetic near fields used for cellular phones in brains of Big Blue mice. Cancer Res (2002) 0.88
Bioassay by intratracheal instillation for detection of lung toxicity due to fine particles in F344 male rats. Exp Toxicol Pathol (2006) 0.88
One-year chronic toxicity study of Aloe arborescens Miller var. natalensis Berger in Wistar Hannover rats. A pilot study. Food Chem Toxicol (2007) 0.87
Lack of a dose-response relationship for carcinogenicity in the rat liver with low doses of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline or N-nitrosodiethylamine. Jpn J Cancer Res (2002) 0.87
Association of prostate cancer and manganese superoxide dismutase AA genotype influenced by presence of occult cancer in control group. Urology (2008) 0.87
Overexpression of orotate phosphoribosyl transferase in hormone-refractory prostate cancer. Oncol Rep (2009) 0.87
A medium-term, rapid rat bioassay model for the detection of carcinogenic potential of chemicals. Toxicol Pathol (2010) 0.86
Comparison of ante- and post-mortem PSA levels for epidemiological studies. Anticancer Res (2005) 0.86
Loss of p57KIP2 is associated with colorectal carcinogenesis. Int J Oncol (2003) 0.86
8-Methoxypsoralen, a potent human CYP2A6 inhibitor, inhibits lung adenocarcinoma development induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Mol Med Rep (2011) 0.85
MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status. In Vivo (2009) 0.85
Update on the diagnosis and management of prostate cancer. Can J Urol (2008) 0.85
Establishment of a bioassay model for lung cancer chemoprevention initiated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice. Exp Toxicol Pathol (2008) 0.84
Periodic analysis of urethane-induced pulmonary tumors in living A/J mice by respiration-gated X-ray microcomputed tomography. Cancer Sci (2008) 0.84
Post-initiation chemopreventive effects of dietary bovine lactoferrin on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in female A/J mice. Cancer Lett (2006) 0.83
Temporal trends and racial disparities in global prostate cancer prevalence. Can J Urol (2014) 0.83
Dose dependent inhibitory effects of dietary 8-methoxypsoralen on NNK-induced lung tumorigenesis in female A/J mice. Cancer Lett (2006) 0.83
Chronic exposure to a 1.439 GHz electromagnetic field used for cellular phones does not promote N-ethylnitrosourea induced central nervous system tumors in F344 rats. Bioelectromagnetics (2005) 0.83
Pathological characteristics of prostate cancer in elderly men. J Urol (2009) 0.83
Study of cyclooxygenase-2 in renal cell carcinoma. Int J Mol Med (2004) 0.83
Lung Carcinogenic Bioassay of CuO and TiO(2) Nanoparticles with Intratracheal Instillation Using F344 Male Rats. J Toxicol Pathol (2009) 0.82
Occurrence of mutations in the epidermal growth factor receptor gene in X-ray-induced rat lung tumors. Cancer Sci (2008) 0.82
Occult prostate cancer effects the results of case-control studies due to verification bias. Anticancer Res (2008) 0.82
Clinicopathological significance of cyclooxygenase-2 expression in hypopharyngeal squamous cell carcinoma. Oncol Rep (2008) 0.82
Chemically modified tetracycline (COL-3) improves survival if given 12 but not 24 hours after cecal ligation and puncture. Shock (2006) 0.82
Gender-dependent effects of gonadectomy on lung carcinogenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female and male A/J mice. Oncol Rep (2013) 0.81
Norepinephrine activates P44 and P42 MAPK in human prostate stromal and smooth muscle cells but not in epithelial cells. Prostate (2003) 0.81
Lack of modifying potential of 8-methoxypsoralen in the promotion or progression stages of lung carcinogenesis in A/J female mice. Oncol Rep (2008) 0.81
Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection. Can J Urol (2006) 0.81
Lack of promoting effects from physical pulmonary collapse in a female A/J mouse lung tumor initiated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) with remarkable mesothelial cell reactions in the thoracic cavity by the polymer. Exp Toxicol Pathol (2010) 0.81
Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor. Carcinogenesis (2005) 0.80
IRX-2 increases the T cell-specific immune response to protein/peptide vaccines. Vaccine (2010) 0.80
Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. Int J Cancer (2002) 0.79
Non-invasive X-ray micro-computed tomographic evaluation of indomethacin on urethane-induced lung carcinogenesis in mice. Anticancer Res (2012) 0.79
Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines. Urol Int (2004) 0.78
The importance of research by urology residents: a thousand points of light. Can J Urol (2007) 0.78
Autopsy evaluation of a prostate cancer case treated with brachytherapy. Anticancer Res (2009) 0.78
Antedrug budesonide by intrapulmonary treatment attenuates bleomycin-induced lung injury in rats with minimal systemic adverse effects. Biol Pharm Bull (2010) 0.78
Lack of Modifying Effects of Intratracheal Instillation of Quartz or Dextran Sulfate Sodium (DSS) in Drinking Water on Lung Tumor Development Initiated with 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in Female A/J Mice. J Toxicol Pathol (2009) 0.78
p27(Kip1)is overexpressed in very early stages of hepatocarcinogenesis. Cancer Sci (2008) 0.78